Using MSOT to Diagnose and Monitor Neuromuscular Diseases in Children
Multispectral Optoacoustic Imaging (MSOT) as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases (MSOT-NMD)
Children's Hospital of Eastern Ontario · NCT06438965
This study is testing a new type of scan to see if it can help doctors diagnose and track the progress of neuromuscular diseases in children without needing invasive procedures.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | Children's Hospital of Eastern Ontario (other) |
| Locations | 1 site (Ottawa, Ontario) |
| Trial ID | NCT06438965 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of Multispectral Optoacoustic Tomography (MSOT) as a non-invasive biomarker for diagnosing and monitoring neuromuscular diseases (NMDs) in children. MSOT scans will be performed on muscle regions to assess hemo/myoglobin, collagen, lipid content, and oxygenation levels in patients with confirmed or suspected NMDs. The study will correlate MSOT data with existing clinical, laboratory, and imaging data from standard care procedures over a period of approximately 36 months, with repeated measurements to track disease progression.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged from birth to 18 years with a confirmed or suspected diagnosis of a neuromuscular disease.
Not a fit: Patients with conditions not consistent with a neuromuscular disease or those with active skin lesions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive method for diagnosing and monitoring neuromuscular diseases in children, potentially improving patient care.
How similar studies have performed: While the use of MSOT in this context is relatively novel, similar imaging techniques have shown promise in other areas of medical diagnostics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with neuromuscular disease * Children (from birth (infants that are born term) to 18 years of age) participants or consent through authorized guardian * Confirmed or suspected diagnosis of a neuromuscular disease (through molecular genetics, biopsy, clinical examination) Exclusion Criteria: Participants: * Diagnosis is not consistent with a confirmed or suspected neuromuscular disease * Patients with active skin lesions (e.g. infections, trauma) or confirmed genetic disorders (e.g. epidermolysis bullosa) that predisposes to skin lesion * Medically unstable patients * Tattoo on skin overlying the area to be examined * Missing consent form * Exclusion due to safety concerns of the investigator (subject who has any condition, including any physical, psychological, or psychiatric condition, which in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data and renders the subject an unsuitable candidate for the study) * Medication leading to increased light sensitivity
Where this trial is running
Ottawa, Ontario
- CHEO — Ottawa, Ontario, Canada (RECRUITING)
Study contacts
- Study coordinator: Hanns Lochmuller, Dr.
- Email: hlochmuller@toh.ca
- Phone: (613) 737-7600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neuromuscular Diseases